Overview

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Status:
Completed
Trial end date:
2019-12-26
Target enrollment:
Participant gender:
Summary
To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Ionis Pharmaceuticals, Inc.
Collaborator:
Ionis Pharmaceuticals, Inc.
Treatments:
Antiviral Agents